The Vanguard Group, Inc. has recently announced that it has increased stake in Amneal Pharmaceuticals Inc (NASDAQ:AMRX) by 3.16%. After grabbing 13.25 million shares, the institutional investor is now in possession of 0.41 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.32% having worth around $57.09 million. Moreover, Rubric Capital Management LP increased its share by 1.42 million to have a control over 4.02 million shares. And Neuberger Berman Investment Advis raised its holdings to 77671.0 shares by acquiring 3.83 million shares or 1.25% of the stake.
Amneal Pharmaceuticals Inc (AMRX) concluded trading on 01/10/24 at a closing price of $5.51, with 2.89 million shares of worth about $15.94 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 81.85% during that period and on Wednesday the price saw a loss of about -3.16%. Currently the company’s common shares owned by public are about 151.49M shares, out of which, 113.16M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 5 analysts are covering the AMRX stock and their offered price forecasts bring an average price target of $6.13. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $7.00 and could fall to a lowest price of $5.50. The stock’s current price level is 9.97% above of average price target set by the analysts, while a rise to estimated low would result in loss of -0.18% for the stock. However, touching the estimated high of $7.00 would mean a gain of 21.29% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 34 times over the past 12 months. They bought 54,748,347 shares in 23 of the transactions. In 11 selling transactions, insiders dumped 169,121 shares.
Vanguard Total Stock Market ETF, Vanguard Small Cap Index Fund, and iShares Russell 2000 ETF are the top 3 mutual funds which are holding stakes in Amneal Pharmaceuticals Inc Vanguard Total Stock Market ETF is currently holding 4.06 million shares of worth totaling $17.51 million. The company recently came buying 0.0 shares which brought its stake up to 1.33% of the company’s outstanding shares. Vanguard Small Cap Index Fund bought 11020.0 shares, after which its hold over company’s outstanding shares expand to 1.17%, leaving 3.58 million shares with the mutual fund that have a worth of about $15.42 million. iShares Russell 2000 ETF, after buying 2.93 million shares, have now control over 0.96% of the stake in the company. It holds 1440.0 shares of worth $12.63 million.
However, the stock later moved at a day high price of 5.73, or with a loss of -3.16%. Stock saw a price change of -5.97% in past 5 days and over the past one month there was a price change of 8.89%. Year-to-date (YTD), AMRX shares are showing a performance of -9.23% which increased to 150.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.24 but also hit the highest price of $6.30 during that period. The average intraday trading volume for Amneal Pharmaceuticals Inc shares is 1.38 million. The stock is currently trading -1.04% below its 20-day simple moving average (SMA20), while that difference is up 13.93% for SMA50 and it goes to 59.49% higher than SMA200.
The Vanguard Group, Inc. acquired 13.25 million shares of Amneal Pharmaceuticals Inc having value of about $57.09 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.41 million shares in the company valued at close to $2232723.63, or have control over 3.16% stake in the company. Amneal Pharmaceuticals Inc (NASDAQ: AMRX) currently have 151.49M outstanding shares and institutions hold larger chunk of about 23.27% of that. Holding of mutual funds in the company is about 11.96% while other institutional holders and individual stake holders have control over 30.68% and 11.42% of the stake respectively.
The stock has a current market capitalization of $1.69B and its 3Y-monthly beta is at 1.35. PE ratio of stock for trailing 12 months is 87.05, while it has posted earnings per share of $0.06 in the same period. It has Quick Ratio of 1.16 while making debt-to-equity ratio of 8.48. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AMRX, volatility over the week remained 4.96% while standing at 5.47% over the month.
Analysts are in expectations that Amneal Pharmaceuticals Inc (AMRX) stock would likely to be making an EPS of $0.09 in the current quarter, while forecast for next quarter EPS is $0.11 and it is $0.58 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.07 which is $0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.23 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -13.12% while it is estimated to decrease by -1.56% in next year.
Analysts at 5 brokerage firms have issued recommendations for the Amneal Pharmaceuticals Inc (AMRX)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 5 Wall Street analysts, 3 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by RBC Capital Mkts on April 07, 2021 offering a Sector perform rating for the stock and assigned a target price of $5 to it.
